AUTHORS: Michael Gold, MD, Susan Taylor, MD, Daniel S Mueller, MD, MBA, Jeffrey Adelglass, MD, Joely Kaufman-Janette, MD, Sue E Cox, MD, Michael Cecerle, MD, Konstantin Frank, MD, Mark Nestor, MD, PhD
SUMMARY: For this post hoc analysis, the authors extracted and analyzed data from the BLESS III study to determine whether there were variances in the effectiveness and safety of letibotulinumtoxinA for treating vertical glabellar lines between the broader female study population and a group of female participants aged 35 to 50. They found that females aged 35 to 50 showed higher rates of improvement at weeks 1, 2, and 4 compared with the remaining female population receiving active treatment. The treatment demonstrated efficacy and safety in treating vertical glabellar lines in this patient group.
